Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Study reveals high burnout among doctors treating sickle cell disease

Hematology-oncology trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in grit and resilience between the two groups.

12 Mar 2026

Review explores how generative AI could support precision oncology decision-making

A narrative review examines how generative AI tools such as large language models and vision-language models could assist precision oncology by interpreting genomic data, matching patients to clinical trials, and synthesizing complex clinical information. The authors emphasize governance, human oversight, and retrieval-based safeguards to ensure these systems are deployed safely in cancer care.

11 Mar 2026

Dual-positive hybrid cells linked to shorter survival in advanced breast cancer

An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

11 Mar 2026

FOXJ1 gene may drive resistance to taxane chemotherapy in advanced prostate cancer

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center.

10 Mar 2026

$Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia$

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them.

9 Mar 2026

Common cardio drugs proven safe in myeloma patients

Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international research.

1 Mar 2026

Blood biomarker guides bladder-sparing treatment decisions for cancer patients

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.

27 Feb 2026

Serial liquid biopsies reveal evolution in advanced prostate cancer

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that androgen receptor (AR) alterations consistently emerged and were linked to poorer outcomes across therapies.

26 Feb 2026

Extreme endurance exercise pushes red blood cells toward accelerated aging

Extreme endurance running damages red blood cells in ways that may affect their ability to function properly, according to a study published in the American Society of Hematology's journal Blood Red Cells & Iron.

18 Feb 2026

ASH releases new guidelines for treating leukemia in adolescents and young adults

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population.

12 Feb 2026

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

11 Feb 2026

Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis

A global research collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and Universitätsmedizin Greifswald (Germany) uncovered why a small number of people developed dangerous blood clots after either receiving certain COVID‑19 vaccines or experiencing a natural adenovirus infection, and the answer lies in an unexpected case of misdirected targeting by the immune system.

11 Feb 2026

Blocking p300 restores chemotherapy sensitivity in resistant tumors

Overcoming tumor resistance to chemotherapy drugs has long been a challenge for oncology clinicians and researchers.

6 Feb 2026

Senescent neutrophils promote tumor survival across cancer types

Renowned as first responders to threatening infections, neutrophils also happen to feature prominently in the microenvironment of tumors, where they and other immune cells play opposing and frequently mutable roles in promoting-or resisting-cancer progression.

6 Feb 2026

New partnership aims to expand global access to sickle cell gene therapy

Caring Cross, a 501(c)(3) non-profit dedicated to improving access to advanced therapies, and Boston Children's Hospital today announced a collaboration to provide a sustainable, affordable pathway for patients to access stem cell gene therapies for the treatment of Sickle Cell Disease (SCD).

22 Jan 2026

Cancer vaccines enter a new era of personalized immunotherapy

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, and effective immunotherapies, particularly when combined with other cancer treatments.

22 Jan 2026